Affordable Access

Access to the full text

Circulating anti-SARS-CoV-2 nucleocapsid (N)-protein antibodies and anti-SARS-CoV-2 spike (S)-protein antibodies in an African setting: herd immunity, not there yet!

Authors
  • Mveang Nzoghe, Amandine1
  • Leboueny, Marielle1
  • Kuissi Kamgaing, Eliane2, 3
  • Maloupazoa Siawaya, Anicet Christel1
  • Bongho, Eliode Cyrien1
  • Mvoundza Ndjindji, Ofilia1
  • Padzys, Guy-Stephan4
  • Ndeboko, Bénédicte1, 3
  • Ategbo, Simon2, 3
  • Djoba Siawaya, Joel Fleury1
  • 1 Centre Hospitalier Universitaire (CHU) - Mère-Enfant), Fondation Jeanne EBORI, Libreville, Gabon , Libreville (Gabon)
  • 2 CHU- Mère-Enfant Fondation Jeanne EBORI, Libreville, Gabon , Libreville (Gabon)
  • 3 Université Des Sciences de La Santé, Libreville, Gabon , Libreville (Gabon)
  • 4 Université Des Sciences Et Techniques de Masuku, Franceville, Gabon , Franceville (Gabon)
Type
Published Article
Journal
BMC Research Notes
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Apr 20, 2021
Volume
14
Issue
1
Identifiers
DOI: 10.1186/s13104-021-05570-3
Source
Springer Nature
Keywords
License
Green

Abstract

ObjectiveHerd immunity is achieved when in a population, immune individuals are in a sufficiently large proportion. Neutralizing antibodies specific to SARS-CoV-2 that are produced following infection or vaccination are critical for controlling the spread of COVID-19. The objective of the present work was to investigate the rate of SARS-CoV-2 natural immunization in Gabonese.ResultsOne thousand, four hundred and ninety two people were enrolled. The overall prevalence of anti-SARS-CoV-2 antibodies was 36.2%. Moreover, 76.4% of people who developed a humoral response to SARS-CoV-2 produced both anti-SARS-CoV-2 N-protein antibodies and anti-SARS-CoV-2 S-protein antibodies, which correspond to 27.7% of the total population. In infants (0–9 month), children (1–17 years) and adults, the prevalence of anti-SARS-CoV-2 antibodies was relatively the same, between 33 and 37% (any antibody types) and between 25 and 28.6% (neutralizing antibodies). In this African context, one-third (1/3) of the screened population was exposed to SARS-CoV-2 and three-quarter (3/4) of those exposed individuals developed neutralizing antibodies against SARS-CoV-2. This data suggest that herd immunity is not yet to be achieved in Gabon.

Report this publication

Statistics

Seen <100 times